Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis.

Heart rhythm - 1 Aug 2023

Zheng Zequn, Song Yongfei, Tan Xuerui

Abstract excerpt

Long QT syndrome type 2 (LQT2) is a genetic disorder caused by mutations in the KCNH2 gene, also known as the human ether-a-go-go-related gene (HERG). More than 30% of HERG mutations result in a premature termination codon that triggers a process called nonsense-mediated messenger RNA (mRNA) decay (NMD), where the mRNA transcript is degraded. NMD is a quality control mechanism that removes faulty mRNA to prevent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon, Nonsense
Share to Cystic Fibrosis
Share to Ether-A-Go-Go Potassium Channels

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Long QT Syndrome

Share to Mutation

Share to Nonsense Mediated mRNA Decay

Share to Oligonucleotides, Antisense

Share to RNA, Messenger

Source

Identifiers

PMID: 37121422
DOI: 10.1016/j.hrthm.2023.04.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis.PMID 37121422Read ↗

Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.Semantic proximity Read ↗

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseasesSemantic proximity Read ↗

Oligonucleotide-based therapies for cystic fibrosis.Semantic proximity Read ↗

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read ↗

The potential of antisense oligonucleotide therapies for inherited childhood lung diseasesSemantic proximity Read ↗

Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTRSemantic proximity Read ↗

Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug DevelopmentSemantic proximity Read ↗

Exon-Skipping Antisense Oligonucleotides for Cystic Fibrosis TherapySemantic proximity Read ↗

Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments.Semantic proximity Read ↗

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotidesSemantic proximity Read ↗

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic FrontiersSemantic proximity Read ↗

Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.